Tandem Diabetes Care, Inc. (TNDM) reported $254.56 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.8%. EPS of -$0.31 for the same period compares to -$0.48 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $254.81 million, representing a surprise of -0.1%. The company delivered an EPS surprise of +8.82%, with the consensus EPS estimate being -$0.34.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Tandem Diabetes Care performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Sales- United States: $179.29 million compared to the $175.14 million average estimate based on three analysts. The reported number represents a change of +5.3% year over year.
  • Geographic Sales- Outside the United States: $75.27 million versus the three-analyst average estimate of $79.95 million. The reported number represents a year-over-year change of +6.8%.
  • Sales- Supplies and Other- Outside the United States: $43.62 million versus $49.27 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1% change.
  • Sales- Pump- Outside the United States: $31.65 million versus the three-analyst average estimate of $30.68 million. The reported number represents a year-over-year change of +19.9%.
  • Sales- Supplies and Other- United States: $96.29 million compared to the $90.97 million average estimate based on three analysts. The reported number represents a change of +13.6% year over year.
  • Sales- Pump- United States: $83 million compared to the $84.17 million average estimate based on three analysts. The reported number represents a change of -2.9% year over year.
  • Revenue- Supplies and Other: $139.91 million versus $140.24 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.6% change.
  • Revenue- Pump: $114.65 million compared to the $114.85 million average estimate based on three analysts. The reported number represents a change of +2.5% year over year.

View all Key Company Metrics for Tandem Diabetes Care here>>>

Shares of Tandem Diabetes Care have returned +29.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research